國家衛生研究院 NHRI:Item 3990099045/11826
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 956886      線上人數 : 830
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11826


    題名: The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
    作者: Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J
    貢獻者: National Institute of Cancer Research
    摘要: Background: mGPS has been identified as a prognostic factor of OS in patients with pancreatic cancer. Here we report the association between mGPS and OS in a post-hoc analysis of the NAPOLI-1 study (NCT01494506), which demonstrated improved survival for nal-IRI+5-FU/LV vs 5-FU/LV in the treatment of patients with mPDAC previously treated with gemcitabine-based therapy. Methods: All patients treated in the NAPOLI-1 study with available baseline plasma Creactive protein (CRP) and albumin data (data cutoff: Nov 16, 2015) were included in this post-hoc analysis. Eligible patients were stratified by mGPS (mGPS-0: CRP ≤10 mg/L regardless of albumin level; mGPS-1: CRP >10 mg/L, albumin ≥35 g/L; and mGPS-2: CRP >10 mg/L, albumin <35 g/L). OS was assessed in individual and pooled treatment arms. A stepwise Cox regression model of OS was used to evaluate the prognostic significance of mGPS. Results: Baseline plasma C-reactive protein and albumin data was available for N = 184 patients: mGPS-0, n = 79; mGPS-1, n = 88; mGPS-2, n = 17. For patients in pooled treatment arms, median OS was worse for the mGPS-1 group than for the mGPS-0 group (4.0 vs 8.0 months, respectively), but was comparable between the mGPS-2 and mGPS-1 groups (3.2 vs 4.0 months, respectively). Multivariate analysis revealed both mGPS-1 and mGPS-2 were independent predictive factors of death (mGPS-1: HR, 3.34; 95% CI, 2.25–4.95, P < 0.0001; mGPS-2: HR, 5.89; 95% CI, 3.21–10.80, P < 0.001). Similarly, analysis by treatment arm showed OS of patients treated with nal-IRI+5-FU/LV was significantly worse in the mGPS-1 (N = 26) and mGPS-2 (N = 5) groups than in the mGPS-0 (N = 27) group (4.6, 3.3 vs 9.3 months, respectively) Conclusions: Data from this post-hoc analyses of mGPS in patients with mPDAC previously treated with gemcitabine-based are consistent with the reports of the prognostic value of the mGPS in estimating OS. Median OS was significantly improved in pts with a mGPS-0 vs mGPS-1 or mGPS-2, including the treatment group of patients receiving nal-IRI+5-FU/LV
    日期: 2018-10
    關聯: Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
    Link to: https://doi.org/10.1093/annonc/mdy282.132
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000459277301328
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081530416
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000459277301328.pdf96KbAdobe PDF243檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋